Abstract
In patients (pts) with coronary artery disease, the correlation between platelet aggregation and clinical outcomes is well established. This correlation is even more evident in high-risk pts, such as patients with diabetes and acute coronary syndromes (ACS) and/or percutaneous coronary interventions (PCI), and those with polyvascular atherosclerotic disease. The use of antiplatelet agents…